Amycretin

Amycretin is a single molecule serving as a GLP-1 receptor agonist and an amylin receptor agonist. It is made by the Danish pharmaceutical company Novo Nordisk as a weight loss drug to be taken by mouth.^[1] A form that can be injected via human skin is also under study.^[1]

Mechanism of action

The drug has a dual mechanism of action affecting appetite regulation and metabolism,^[2] which makes it different from other drugs being made for weight loss.^[2]

Research

The company announced the results from the Phase I trial of amycretin's pill form.^[3] The company further announced the results of its 1B/2A trial in January 2025.^[4] The trial investigated the drug's safety, tolerability, and pharmacokinetics by injecting it into 125 patients via their skin.^[4] The treatment lasted up to 36 weeks.^[4]

References

↑ ^1.0 ^1.1
- Jamaluddin, Aqfan; Gorvin, Caroline M (2023-03-21). "RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis". Journal of Molecular Endocrinology. Bioscientifica. 70 (4). doi:10.1530/jme-23-0014. ISSN 0952-5041. PMC 10160555. {{cite journal}}: Check |pmc= value (help)
- Melson, Eka; Ashraf, Uzma; Papamargaritis, Dimitris; Davies, Melanie J. (February 1, 2024). "What is the pipeline for future medications for obesity?". International Journal of Obesity: 1–19. doi:10.1038/s41366-024-01473-y. ISSN 1476-5497.
- Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663.
- Linnane, Ciara. "Viking Therapeutics faces higher bar for oral weight-loss drug" (in EN-US). MarketWatch. https://www.marketwatch.com/story/viking-therapeutics-faces-higher-bar-for-oral-weight-loss-drug-after-strong-readout-from-rival-72c531c4. Retrieved March 11, 2024.
- Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663. ISSN 1467-7881.
↑ ^2.0 ^2.1 Gasiorek A, Heydorn A, Kirkeby K, Key C, Toubro S, Schefe LH, Dahl K, Hjerpsted JB, Vegge A (September 2024). "Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study". Diabetologia. Springer. 67: S42–S43.
↑ ""Novo valuation surpasses Tesla on experimental obesity drug data"". Reuters. March 7, 2024. Retrieved 2024-03-13.
↑ ^4.0 ^4.1 ^4.2 "Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity". Novo Nordisk. January 24, 2025. Retrieved 2025-01-29.

This short article about medicine can be made longer. You can help Wikipedia by adding to it.

[A-1] 1.0 ^1.1
Jamaluddin, Aqfan; Gorvin, Caroline M (2023-03-21). "RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis". Journal of Molecular Endocrinology. Bioscientifica. 70 (4). doi:10.1530/jme-23-0014. ISSN 0952-5041. PMC 10160555. {{cite journal}}: Check |pmc= value (help)

Melson, Eka; Ashraf, Uzma; Papamargaritis, Dimitris; Davies, Melanie J. (February 1, 2024). "What is the pipeline for future medications for obesity?". International Journal of Obesity: 1–19. doi:10.1038/s41366-024-01473-y. ISSN 1476-5497.

Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663.

Linnane, Ciara. "Viking Therapeutics faces higher bar for oral weight-loss drug" (in EN-US). MarketWatch. https://www.marketwatch.com/story/viking-therapeutics-faces-higher-bar-for-oral-weight-loss-drug-after-strong-readout-from-rival-72c531c4. Retrieved March 11, 2024.

Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663. ISSN 1467-7881.

[2] Jamaluddin, Aqfan; Gorvin, Caroline M (2023-03-21). "RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis". Journal of Molecular Endocrinology. Bioscientifica. 70 (4). doi:10.1530/jme-23-0014. ISSN 0952-5041. PMC 10160555. {{cite journal}}: Check |pmc= value (help)

[3] Melson, Eka; Ashraf, Uzma; Papamargaritis, Dimitris; Davies, Melanie J. (February 1, 2024). "What is the pipeline for future medications for obesity?". International Journal of Obesity: 1–19. doi:10.1038/s41366-024-01473-y. ISSN 1476-5497.

[4] Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663.

[5] Linnane, Ciara. "Viking Therapeutics faces higher bar for oral weight-loss drug" (in EN-US). MarketWatch. https://www.marketwatch.com/story/viking-therapeutics-faces-higher-bar-for-oral-weight-loss-drug-after-strong-readout-from-rival-72c531c4. Retrieved March 11, 2024.

[6] Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663. ISSN 1467-7881.

[B-2] 2.0 ^2.1 Gasiorek A, Heydorn A, Kirkeby K, Key C, Toubro S, Schefe LH, Dahl K, Hjerpsted JB, Vegge A (September 2024). "Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study". Diabetologia. Springer. 67: S42–S43.

[3] ""Novo valuation surpasses Tesla on experimental obesity drug data"". Reuters. March 7, 2024. Retrieved 2024-03-13.

[C-4] 4.0 ^4.1 ^4.2 "Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity". Novo Nordisk. January 24, 2025. Retrieved 2025-01-29.

[1]

[2]

[3]

[4]